All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research ... foreign exchange assumptions and product-level adjustments. These factors contribute ...

Pfizer Inc. (NYSE:PFE), one of the ... Check out our ProPicks platform to find out and take your investment strategy to the next level. To evaluate PFE further, use InvestingPro’s Fair Value ...

Pfizer's second-quarter results for 2024 ... Check out our ProPicks platform to find out and take your investment strategy to the next level. To evaluate PFE further, use InvestingPro’s Fair ...

My DCF analysis suggests stock ought to be valued ~$50, but this depends on the business becoming ... believing “this will be Pfizer's year” is a comparable strategy. Pfizer stock began ...

Starboard has around $1 billion stake and has criticized CEO Deadline passed for nominating board members for this year Pfizer Inc. got a reprieve — at least for now — in its battle with activist ...